Benitec Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
15/11/2024 14:06
* Benitec Biopharma Inc BNTC.OQ reported a quarterly
adjusted
loss of 48 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-2.76. The mean expectation of three analysts
for the quarter was for a loss of 55 cents per share. Wall
Street expected results to range from -67 cents to -44 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Benitec Biopharma Inc's reported EPS for the quarter was a
loss
of 48 cents.
* The company reported a quarterly loss of $5.06 million.
* Benitec Biopharma Inc shares had risen by 13.2% this
quarter and
gained 222.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 30%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Benitec Biopharma
Inc is $20.00
This summary was machine generated from LSEG data November 15 at
02:06 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.55 -0.48 Beat
Jun. 30 2024 -0.49 -1.32 Missed
Mar. 31 2024 -0.78 -1.64 Missed
Dec. 31 2023 -0.39 -2.64 Missed